New drug cocktail aims to shrink head and neck tumors
NCT ID NCT04643379
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (olaparib, pembrolizumab, and carboplatin) as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this mix works better than the standard treatment at shrinking tumors. About 30 adults with incurable disease will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- Sharper radiation boost aims to tackle head and neck cancers that return
- New combo attack: immunotherapy plus chemo before surgery for head and neck cancer
- Leftover immunotherapy may boost chemo: new study investigates timing
- New drug cocktail shows promise for tough head and neck cancers